Magazine article from our research archive:

Panel slams OxyContin trials and says abuse, mortality risks persist.(NEWS FROM THE FDA)

In reviewing the tamper-resistant version of OxyContin, a Food and Drug Administration joint panel criticized the trials that were used to demonstrate the new formulation's abuse-proof qualities.

Maker Purdue Pharma LP said it reformulated its currently marketed OxyContin (oxycodone hydrochloride controlled release) to provide "'resistance to certain methods used to defeat the controlled-release mechanism."

But members of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management advisory committees blasted Purdue's in vitro trials, saying the poor scientific rigor of the trials was almost insulting.

OxyContin can be crushed easily between two ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!